20 results about "Lupeol" patented technology

The invention discloses an efficient targeting anti-hepatic fibrosis nano drug delivery system and a preparation method thereof. According to the system, a pentacyclic triterpenoid compound lupeol extracted from cichorium glandulosum is taken as an active ingredient, and the hyaluronic acid modified ZIF-8 loaded lupeol nano drug delivery system (HA / Lupeol ZIF-8) is constructed aiming at the problems of poor water solubility, low stability, weak targeting property and the like of the pentacyclic triterpenoid compound lupeol. The system is synthesized by a room-temperature solution method, hydrophobic lupeol is efficiently entrapped by using a porous structure of ZIF-8, and active targeting of a CD44 receptor on the surface of the hepatic stellate cell is realized by surface modification of hyaluronic acid. The particle size of the nano drug delivery system is 50-200nm, the encapsulation efficiency is 97.4%, and the drug loading capacity is 23.8%. In a fibrotic acidic microenvironment, the ZIF-8 carrier can responsively degrade and release a drug, and effectively penetrates through a collagen deposition barrier, so that precise drug delivery is realized. According to the invention, a new strategy is provided for anti-hepatic fibrosis treatment by combining degradation of ZIF-8 in a hepatic fibrosis acidic microenvironment and active targeting bifunctional characteristics of hyaluronic acid for the first time.

To provide wound-healing formulations containing solid birch bark extracts that may be applied to the skin without worsening the patient's condition.SOLUTION: A solid birch bark extract comprises at least about 70 wt.% of betulin, and one or more triterpenes selected from the group consisting of betulinic acid, oleanolic acid, erythrodiol, and lupeol.SELECTED DRAWING: None

This invention belongs to the field of testing and analysis technology, and discloses a method for rapidly extracting and detecting the content of various terpenoids and sterols in rubber grass. The specific steps are as follows: Step 1: Preparation of standard solutions of terpenoids and sterols. Detection is performed using a general-purpose high-performance liquid chromatograph, eliminating the need for large-scale precision mass spectrometry equipment, resulting in lower purchase and maintenance costs. The operation process is simple and easy to learn, meeting the needs of high-throughput rapid detection of batch samples. A single sample test only takes 35-60 minutes, significantly improving detection efficiency. It can simultaneously complete the qualitative identification and content determination of five target components, including lupeol and taraxasterol. The method has good repeatability and high accuracy, with excellent linearity of the standard curve, and stable and reliable detection results. By optimizing the extraction solvent, temperature, time, and isocratic elution chromatographic conditions, the target components are fully extracted and separated effectively, allowing for accurate acquisition of the content data of each component.

The invention relates to a gynostemma pentaphylla oxidized squalene cyclase gene GpOSC2 and application thereof, and belongs to the technical field of genes. The amino acid sequence of the gynostemma pentaphylla oxidized squalene cyclase GpOSC2 is as shown in SEQ ID NO. 1. A coding sequence for coding the gynostemma pentaphylla oxidized squalene cyclase GpOSC2 gene is a nucleotide sequence as shown in SEQ ID NO. 2. According to the present invention, the gene is adopted to carry out fermentation so as to obtain Dammarenediol-II, lupeol, lanosterol, cycloartenol and alpha-amyrin alcohol, such that the application prospect is good, and the promotion and the application are easy.

The invention relates to a method for extracting lupeol from green mango peel, which comprises the following steps: by taking green mango peel as a raw material and taking an ethyl acetate solution as an extracting agent, comparing and analyzing the mass fraction content and extraction efficiency of lupeol extracted by three extraction methods of Soxhlet extraction, microwave extraction and ultrasonic extraction; the ultrasonic extraction method is optimized, so that the optimal lupeol extraction method is obtained. The method is simple in process operation, low in production cost and high in extraction efficiency, the yield of lupeol is increased from the angle of turning waste into wealth, the utilization rate of green mangoes is increased, and the concept of green, environment-friendly and low-carbon utilization is achieved.

This invention relates to vesicle-loaded lupeol derivative nanoparticles, their preparation method, and applications. The invention utilizes probiotic-constructed artificial membrane vesicles loaded with the chemical drug lupeol quaternary ammonium salt derivative, effectively addressing the shortcomings of lupeol quaternary ammonium salt derivatives in terms of targeting and solubility in colorectal cancer. The carrier material is derived from natural intestinal probiotics, possessing a certain degree of biosafety; simultaneously, the carrier material itself also exhibits intestinal function regulation and immune-inducing effects, and can synergistically enhance the anti-colorectal cancer efficacy of lupeol quaternary ammonium salt derivatives, achieving an immunotherapy effect.

The invention discloses an application of lupeol as an FLI1 protein inhibitor in preparation of an anti-erythroleukemia drug, and belongs to the technical field of biological medicines, and the lupeol plays an anti-erythroleukemia role by inhibiting erythroleukemia cell proliferation and / or inducing erythroleukemia cell apoptosis. The lupeol is directly combined with the FLI1 protein and reduces the expression level of the FLI1 protein to realize the FLI1 protein inhibition effect. The invention reveals and verifies that the natural compound lupeol can inhibit the expression and function of the FLI1 protein by directly targeting and combining with the FLI1 protein for the first time, thereby playing a role in resisting erythroleukemia. A brand-new FLI1 protein inhibition-based action mechanism is provided for the treatment of erythroleukemia, and the limitation that the existing treatment means mainly depends on traditional cytotoxic drugs is broken through.

The present application relates to a kind of isopentenyl diphosphate isomerase mutant and the method and application for improving the production of lipojan Yarrowia in lupinol, belong to genetic engineering technical field.The isopentenyl diphosphate isomerase mutant is obtained by rational design screening based on the amino acid sequence shown in SEQ ID NO.1.The present application constructs the recombinant strain Po1FK01 of the production of lipojan Yarrowia Po1f strain basis lupinol, the isopentenyl diphosphate isomerase mutant constructed is transformed into the recombinant strain and is expressed, and the activity of each mutant is characterized with the production of lupinol.Compared with control strain, i.e.unmutated strain, the production of lupinol in lipojan Yarrowia engineering bacteria overexpressing isopentenyl diphosphate isomerase mutant YlIDI1 (K78R+S129D) is increased by about 86%.The present application provides strong enzyme and strain for the biosynthesis of lupinol, and has important significance for the production of lupinol.

The invention relates to a composition for oral or topical human administration and a preparation method thereof. The present invention relates to pentacyclic triterpenoid compounds wherein said triterpenoid compounds are incorporated into lipid vesicles, preferably cream globules, surrounded by three layers of membranes. The triterpenoid is preferably betulinic acid, and / or betulinol, and / or lupenol, and / or oleanolic acid, and / or ursolic acid, most preferably betulinic acid. The incorporation of the triterpenoid compound into the milk fat globules or lipid vesicles at a high payload of at least 10 to at most 50 mg / ml is preferably accomplished with high energy emulsification techniques, most preferably ultrasound treatment. The composition is present as a liquid emulsion formulation in a preferred embodiment. In another preferred embodiment, the composition is a powder, which can be prepared from a liquid embodiment of the composition by, for example, spray drying or freeze drying techniques. The composition can be preferably used as a medicament, a food supplement or a nutraceuticals for the treatment or prevention of cancer, type 2 diabetes, obesity and cardiovascular diseases.

The application discloses a beta-1, 6-glycosidic bond hydrolytic enzyme and application thereof in traditional Chinese medicine resources. The method screens a key gene sequence with a function of hydrolyzing beta-1, 6-glycosidic bond from a Candida parapsilosis L7 genome, and names the key gene sequence as CoExg1. A gene engineering bacterium capable of efficiently heterologously expressing CoExg1 is constructed by using a molecular cloning technology. After fermentation and enzyme production, an enzyme catalytic reaction system is established, and a traditional Chinese medicine active molecule in mogroside V is directionally converted, beta-1, 6-glycosidic bonds in different regions of a substrate structure are selectively hydrolyzed, and therefore, efficient and phased synthesis of different products such as sianoside I and mogroside IIIE is realized. In addition, CoExg1 can also hydrolyze beta-glycosidic bonds in the structures of icariin and lupeol, and directionally synthesize icariin II and lupeol, thereby providing important technical support for high-value utilization of traditional Chinese medicine resources and quality improvement and efficiency enhancement of traditional Chinese medicine glycosides.

The application discloses a culture solution containing lupeol for improving in-vitro maturation efficiency of pig oocytes and application thereof. The application adds lupeol, especially 4 muM lupeol, to an in-vitro maturation culture solution of oocytes, which can effectively improve the oxidation-reduction state of oocytes, significantly reduce the intracellular ROS level, and meanwhile, improve the GSH content, thereby maximally relieving oxidative stress damage in the in-vitro maturation process, significantly improving the maturation rate of pig oocytes in the meiotic metaphase II, and effectively reducing the DNA fragmentation ratio, which indicates that the lupeol has excellent effects of promoting nuclear maturation and protecting genetic material. The lupeol is added to the in-vitro maturation culture solution of oocytes, which is easy to operate and can be applied to the existing culture process, and can stably improve the efficiency and quality of pig in-vitro embryo production, and has important application value for pig germplasm resource preservation, rapid propagation of excellent breeds and development of animal husbandry.

The invention discloses a method for predicting a liver cancer immune drug resistance scheme of formononetin targeting ERalpha36. The method comprises the following steps: acquiring current multi-modal pathological data of a liver cancer patient; inputting the current multi-modal pathological data into a multi-modal graph neural network to predict a treatment scheme to obtain formononetin treatment schemes of the liver cancer patient under different drug resistance probabilities; the multi-modal graph neural network is constructed by training a graph attention network carrying ERalpha36 bias enhancement based on a historical experiment data set; the historical experiment data set comprises historical multi-mode pathological data with a corresponding relation and formononetin treatment schemes under various historical drug resistance probabilities; according to the Shapley value, quantifying an accumulated contribution value corresponding to the formononetin treatment scheme under each drug resistance probability; and determining the formononetin treatment scheme under the drug resistance probability corresponding to the highest accumulated contribution value as the optimal treatment scheme for the liver cancer patient. The application can improve the effectiveness and safety of immune drug-resistant treatment of liver cancer.

The present application belongs to the technical field of biological medicine, and particularly relates to an oral preparation of lipoxygenase of a healthy donor treatment type intestinal flora exosome package and a preparation method and application thereof. The oral preparation of lipoxygenase of a healthy donor treatment type intestinal flora exosome package comprises 0.18-0.78wt% lipoxygenase, 0.24-0.48wt% fucoidan, 1.0-2.0wt% tetrahydropyrimidine and a healthy donor treatment type intestinal flora exosome supplementing to 100% according to weight percentage. The present application adopts an ultrasonic method to prepare the lipoxygenase of a healthy donor treatment type intestinal flora exosome package, uses the treatment type intestinal flora exosome as a natural medicine carrier, successfully solves the technical problem of low oral bioavailability of lipoxygenase, and provides a new effective means for enhancing immunity and preventing and treating tumors.

The invention relates to an isopentene diphosphate isomerase mutant, a method for improving lupeol produced by yarrowia lipolytica and application of the isopentene diphosphate isomerase mutant, and belongs to the technical field of genetic engineering. The isopentene diphosphate isomerase mutant is obtained by rational design and screening on the basis of an amino acid sequence as shown in SEQ ID NO.1. According to the invention, a recombinant strain Po1FK01 for producing lupeol is constructed on the basis of a yarrowia lipolytica Po1f strain, the constructed isopentene diphosphate isomerase mutant is transformed into the recombinant strain for expression, and the activity of each mutant is characterized by the yield of lupeol. Compared with a control strain, namely a non-mutated strain, the yield of lupeol in the yarrowia lipolytica engineering strain of the overexpressed isopentene diphosphate isomerase mutant Y1IDI1 (K78R + S129D) is increased by about 86%. The invention provides powerful enzyme and bacterial strain for the biosynthesis of lupeol, and has important significance for the production of lupeol.

The invention provides an application of lupinus luteus (Lupilightteone, Lup) in preparation of a medicine for preventing or treating kidney diseases, and relates to the field of medicines for preventing or treating kidney diseases. The Lup provided by the invention can protect renal tubular epithelial cells, significantly increase the activity of acute kidney injury cells, significantly improve the glomerular filtration function of mice, improve the pathological injury degree of kidneys and reduce renal fibrosis. The invention provides a new thought for developing medicines for preventing or treating kidney diseases.

The application belongs to the technical field of cell culture, and particularly relates to a kind of extracellular vesicles containing active mitochondria and a preparation method thereof.The preparation method specifically comprises the following steps: culturing mitochondrial donor cells until the fusion degree reaches 70-80%, discarding the original culture medium, adding DMEM / F12 culture medium containing exosome-free fetal bovine serum, verbascoside and lupeol for continuous culture; collecting cell culture supernatant, and after multiple centrifugation and microporous filter filtration, centrifuging to collect the precipitate, thereby obtaining extracellular vesicles rich in active mitochondria.The extracellular vesicles obtained by the preparation method of the application can significantly promote the proliferation of UVB-induced photoaging human skin fibroblasts, inhibit the expression of senescence-associated proteins p16 and p21, have the effects of repairing photoaging damage and reversing cell senescence, and have a broad application prospect.

The invention belongs to the technical field of biology, and particularly relates to application of lupeol to preparation of a medicine for preventing or treating renal injury caused by cis-platinum. The invention discovers that the natural compound lupeol has a potential protection effect on the renal injury caused by the cis-platinum for the first time, and in-vivo and in-vitro models prove that the lupeol remarkably relieves renal dysfunction, tissue pathological injury and rising of renal injury markers caused by the cis-platinum, inhibits cell apoptosis and promotes proliferation of renal tubular cells. A transcriptome sequencing result shows that lupeol enhances cell survival and proliferation by activating a PI3K / Akt signal channel, regulates an Nrf2 channel to resist oxidative stress, inhibits nuclear translocation of NF [kappa] B, reduces pro-inflammatory cytokines and inhibits inflammatory response. Results show that lupeol may become a choice for relieving renal toxicity of cis-platinum.

The invention is applicable to the technical field of natural product extraction and medical application, and provides an extraction method of lupeol in lugoseris and antiviral application thereof.The extraction method of lupeol in lugoseris comprises the following steps that S1, raw material pretreatment is conducted, specifically, the whole herb of lugoseris is subjected to vacuum drying under the condition of 40-60 DEG C till the moisture content is smaller than or equal to 8%, and the dried lupeol is obtained; the preparation method comprises the following steps: crushing, sieving to 20-40 meshes, adding 5-10 times by volume of deionized water with pH of 6.5-7.0, soaking for 6-12 hours, stirring once every 2 hours during soaking, filtering, and washing for 3 times by using ultrapure water to remove polysaccharide and water-soluble pigment; the pretreated raw materials and an ethanol solution with the volume fraction of 70%-90% are mixed according to the material-liquid ratio of 1: 10-1: 20, ultrasonic-assisted reflux extraction is carried out at the temperature of 60-80 DEG C, the ultrasonic frequency is 40 kHz, the power is 300 W, extraction is carried out for 1-2 hours each time and repeated for 2-3 times, and extracting solutions are combined and then filtered through a 0.22-micron microporous membrane. According to the extraction method of lupeol in the pond snake, provided by the scheme, the extraction efficiency and antiviral activity of lupeol are remarkably improved.

The application discloses a lupine alcohol as an MSTN inhibitor and application thereof in preparing products for improving or preventing and treating muscle atrophy, and belongs to the technical field of biological medicine. The application first discovers that the lupine alcohol can be used as a small molecule inhibitor of myostatin (MSTN); in-vitro cell experiments prove that the lupine alcohol can effectively antagonize the proliferation inhibition and differentiation inhibition of C2C12 myoblasts by MSTN, and block the MSTN / Smad signal pathway. In-vivo animal experiments further prove that in a muscle injury model induced by barium chloride (BaCl2), the lupine alcohol can promote skeletal muscle regeneration; in a muscle atrophy model induced by dexamethasone (DEX), the lupine alcohol can effectively relieve the decrease of muscle function and muscle fiber atrophy. The application provides a new, safe and effective natural candidate molecule for improving and / or preventing and treating muscle atrophy, especially senile muscle atrophy, and can be used for preparing medicines, health products, functional foods or dietary supplements, and has a wide application prospect.

The present application relates to the field of plant transgenic technology, and particularly relates to application of BpLUS1 gene in regulating branch number and / or lupine alcohol content of white birch. Overexpression of the BpLUS1 gene can increase the branch number and the lupine alcohol content of the plant. The results of the specific embodiments of the present application show that: by regulating the expression amount of the BpLUS1 gene through genetic engineering, the branch number of the plant can be significantly increased, so as to improve the overall biomass of the plant; by regulating the expression amount of the BpLUS1 gene through genetic engineering, the synthesis and accumulation of target metabolites (such as lupine alcohol) are improved, and the medicinal or commercial value of the plant is improved. Moreover, the BpLUS1 gene can simultaneously regulate multiple traits (branch development and metabolite synthesis) of the plant, so that the growth and development and production performance of the plant can be better optimized.